SCHEMBL6491981

SCHEMBL6491981

CS(=O)(=O)Oc1cccc(N2CCN(C(=O)c3c4ccccc4nc4ccccc34)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 6/20 0.48
LMNA P02545 5/20 0.48
KDM4E B2RXH2 3/20 0.48
GAA P10253 1/20 0.48
MGLL Q99685 2/20 0.48
ACACB O00763 1/20 0.47
ACACA Q13085 1/20 0.47
TSHR P16473 3/20 0.45
RAB9A P51151 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
USP2 O75604 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18854912 0.87 KMT2A (0.66) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6480776 0.85 KMT2A (0.53) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6491894 0.84 KMT2A (0.52) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6481517 0.83 KMT2A (0.53) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6479149 0.82 KMT2A (0.49) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6481434 0.82 LMNA (0.49) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6479667 0.81 KMT2A (0.48) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6481219 0.81 DRD4 (0.54) KMT2AALDH1A1LMNAKDM4EGAA
Dimethylamine SCHEMBL6533378 0.81 KMT2A (0.48) KMT2AALDH1A1LMNAKDM4EGAA
SCHEMBL6488791 0.81 KMT2A (0.58) KMT2AALDH1A1LMNAKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors ZENTARIS GMBH (DE) 2005-01-13 US claimed
WO-2005007643-A1 NOVEL ACRIDINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS ZENTARIS GMBH (DE) 2005-01-27 WO disclosed
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors ZENTARIS GMBH (DE) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors PKD1, MDH2, MSH2 KMT2A 1945/4885ALDH1A1 23/4885LMNA 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.